"We expect digital life science platforms to be mainstream in the next five to 10 years, enabling them to nimbly adapt their business and operating models in response to external disruption and change in business strategy.” In the prescribed digital therapeutics (PDTs) sector, Gartner suggests that companies “seek partnerships with technology vendors that have the capabilities to develop and scale the technologies needed for digital therapeutic deployment.” The report further notes that, “The success of PDTs depends on identifying the right commercial model and partners that have aligned incentives, cultural fit, defined expectations and open communications.”Īs CIOs continue to build advanced analytics, one thing is certain: the life sciences industry is heading toward a platform approach. To ensure the success of their investments in digital tools and solutions, life sciences organizations are forming more partnerships across the healthcare ecosystem. “Because the path forward is uncertain, CIOs will need to develop a technology strategy that is adaptable, scalable and resilient to meet new business requirements on demand,” Gartner states. As CIOs continue to hone their long-term technology strategies, understanding the maturity level and efficiency of each product in their portfolio is paramount.
In response to the pandemic, these organizations “immediately accelerated the application of advanced analytics technologies to personalize customer engagement, deploy new digital channels, advance patient-engagement strategies and pursue new health value creation opportunities.”īut with the leap toward newfound technology adoption comes the challenge of scale. “For an industry that traditionally has taken a conservative approach to adopting emerging technologies, life science organizations (LSOs) were thrust into the digital era almost overnight,” Gartner notes in the latest Hype Cycle TM report 1.
0 kommentar(er)
